Age Spots and Sun Pigmentation: What the Evidence Actually Supports

Age Spots and Sun Pigmentation: What the Evidence Actually Supports

The short version

  • Age spots are solar lentigines: decades of sun settled into one patch of skin. They do not fade like a recent mark.
  • The pooled trial evidence favours in-clinic lasers and prescription topicals. No cosmetic serum comes close (Mardani, 2025).
  • Daily sunscreen has the best evidence here, but that trial measured skin texture, not spots (Hughes, 2013).
  • Vitamin C is better supported for limiting new pigment than for clearing old marks (De, 2019).
  • Niacinamide and oxyresveratrol have sensible mechanisms and thin human data. We sell these, so mind the funding notes.

What an age spot actually is

The flat brown marks on cheeks, temples, forearms and the backs of the hands are usually solar lentigines.

Freckles are largely genetic. Lentigines are induced by sun exposure and accumulated photodamage (Praetorius, 2014): a settled change built up over decades.

Why the correctors on the shelf underperform

A systematic review pooled 41 trials in 3,234 patients aged 24 to 92. Reported success rates:

  • Intense pulsed light: 74.6 to 90 per cent
  • Picosecond lasers: 67.9 to 93 per cent
  • Fractional CO2: 8 to 23 per cent
  • Prescription mequinol with tretinoin: 52.6 to over 80 per cent

The authors still called for larger randomised trials (Mardani, 2025). Nothing on that list is a cosmetic serum.

A double-blind cysteamine study says up front that topical depigmenting products, hydroquinone included, are usually ineffective on lentigines. It found a 40 per cent reduction in colour readings against 2 per cent for vehicle, but ran 12 weeks in 30 patients (Saki, 2024).

Sunscreen has the best evidence, but not on the spots

The Nambour trial randomised 903 Queensland adults under 55 to daily broad-spectrum sunscreen or discretionary use. Over four and a half years the daily group showed 24 per cent less skin ageing (Hughes, 2013).

The honest limit: the outcome was skin microtopography, meaning surface texture taken from moulds. Nobody counted pigmented spots.

In its favour, it ran four and a half years on public funding. No trial has compared sunscreen against a serum head to head.

Visible light and tinted sunscreen

Broad-spectrum sunscreen covers ultraviolet but not visible light, which can drive pigmentation, especially in deeper skin tones. A sunscreen has to be visible on the skin to block visible light, so tinted formulas with iron oxides work where nanoparticle filters do not (Lyons, 2021).

Two caveats: it is a narrative review rather than a trial, and one author works at a sunscreen company. Sensible rather than proven.

Vitamin C, including C-Tetra

A meta-analysis pooled 31 randomised, vehicle-controlled studies in 741 volunteers. Vitamin C reduced ultraviolet-induced pigment but added nothing during the depigmentation phase, so the authors called it antipigmenting rather than depigmenting (De, 2019).

Read the design first:

  • Volunteers were 18 to 50 with phototype III skin.
  • The pigment was raised deliberately over four days, so it was a fresh tan, not a decades-old lentigo.
  • All authors are employees of L'Oreal.

An independent review found significant lightening across seven publications and 139 volunteers, though in melasma and photodamage, not lentigines (Correia, 2023).

Medik8 C-Tetra uses tetrahexyldecyl ascorbate, chosen for stability. The most relevant study ran 12 weeks in 35 people, open-label with no control, on a competitor's serum funded by Image Skincare (Min, 2024). Evidence about an ingredient, not the bottle we sell.

Niacinamide

Niacinamide did not affect tyrosinase in cultured melanocytes, but inhibited melanosome transfer to keratinocytes by 35 to 68 per cent. In the human arm, 18 Japanese women used 5 per cent niacinamide against vehicle and showed decreased pigmentation at four weeks (Hakozaki, 2002).

Eighteen people over four weeks is small and short, and the lead author is listed with a Procter and Gamble affiliation, so this is industry work on an ingredient the company sells.

The paper gives neither their ages nor the type of marks, so we cannot say it was tested on age spots at all.

Oxy-R and oxyresveratrol

Medik8 Oxy-R is built around oxyresveratrol, and most work on it is laboratory work. It inhibited tyrosinase in vitro more effectively than resveratrol, with effects on melanin in a reconstituted skin model (Park, 2014). That is cell culture, not spots on a face.

There is one human trial, of 1 per cent oxyresveratrol (Zhang, 2026). It was run on facial melasma, carries no abstract on PubMed, and every author is listed at the biotechnology companies behind the ingredient. We found no randomised trials of it on solar lentigines.

What we would actually do

  • Be most consistent about daily sun protection, remembering that trial measured texture, not marks.
  • If uneven colour is the main concern, consider a tinted sunscreen, on review reasoning rather than trial evidence.
  • Use vitamin C as a daytime antioxidant and judge it over months, not weeks.
  • Niacinamide is inexpensive and easy to include. Hold the evidence loosely.
  • If an established lentigo is what bothers you, the evidence favours in-clinic procedures and prescription topicals. We are a shop with a treatment room, not a laser clinic. That is a conversation for a qualified practitioner.

Everything above is about the appearance of skin. Nothing sold here treats, cures or prevents a medical condition.

If a mark is new, changing or asymmetrical, see a doctor rather than a serum.

The Verdo team

Frequently asked questions

Will a vitamin C serum fade age spots I already have?
The evidence is better for limiting new pigment than for clearing old marks. A meta-analysis of 31 randomised vehicle-controlled studies in 741 volunteers found vitamin C reduced ultraviolet-induced pigment but added nothing during the depigmentation phase, so the authors called it antipigmenting rather than depigmenting. Those volunteers were 18 to 50 with phototype III skin and the pigment was raised deliberately over four days, so it was fresh pigment in younger skin, not a decades-old lentigo.
Is Medik8 C-Tetra as well studied as ordinary L-ascorbic acid?
No. The most relevant study of tetrahexyldecyl ascorbate ran 12 weeks in 35 people, was open-label with no control group, and tested a competitor's serum funded by Image Skincare. That is evidence about an ingredient rather than about the bottle we sell, and the case for a stable derivative rests on formulation chemistry rather than a head-to-head trial.
What does the research say about Oxy-R and oxyresveratrol?
Mostly laboratory work. Oxyresveratrol inhibited tyrosinase in vitro more effectively than resveratrol, but that measured enzyme activity and cell models, not spots on a face. The one human trial was run on facial melasma rather than age spots, carries no abstract on PubMed, and every author is listed at the biotechnology companies behind the ingredient; we found no randomised human trials of it on solar lentigines.
How strong is the evidence for daily sunscreen here?
It is the longest and best-controlled trial in this area. The Nambour trial randomised 903 Queensland adults under 55 and found 24 per cent less skin ageing over four and a half years with daily use, funded publicly rather than by industry. But the outcome measured was skin surface texture, not pigmented spots, so it does not tell you what happened to anyone's age spots.
Should I use a tinted sunscreen?
It is worth considering if uneven colour is your main concern, because standard sunscreens cover ultraviolet but not visible light, and a sunscreen has to be visible on the skin to block it. The source is a narrative review rather than a trial, and one of its authors works at a sunscreen company. Treat it as sensible reasoning rather than settled.
Back to blog

Keep reading